OBJECTIVE: The purpose of this study was to compare an in vivo test of whole-body glycolysis, the deuterated-glucose disposal test (2H-GDT), with insulin sensitivity measured by the euglycemic-hyperinsulinemic glucose clamp and the steady-state plasma glucose (SSPG) test. RESEARCH DESIGN AND METHODS: The 2H-GDT consists of an oral glucose challenge containing deuterated glucose, followed by measurement of heavy water (2H2O) production, which represents whole-body glycolytic disposal of the glucose load. 2H2O production is corrected for ambient insulin concentration as an index of tissue insulin sensitivity. The 2H-GDT was compared with euglycemic-hyperinsulinemic glucose clamps in healthy lean subjects (n = 8) and subjects with the metabolic syndrome (n = 9) and with the SSPG test in overweight (n = 12) and obese (n = 6) subjects. RESULTS: A strong correlation with the clamp was observed for the 75-g and 30-g 2H-GDT (r = 0.95, P < 0.0001 and r = 0.88, P < 0.0001, respectively). The 2H-GDT and clamp studies revealed marked insulin resistance in subjects with metabolic syndrome compared with lean control subjects. The correlation with the clamp was maintained in each group (lean, r = 0.86, P < 0.01; metabolic syndrome, r = 0.81, P < 0.01) for the 75-g test. The 2H-GDT also correlated strongly with the SSPG test (r = -0.87, P < 0.0001) in overweight and obese subjects. CONCLUSIONS: The 2H-GDT, which measures whole-body glycolysis in humans in a quantitative manner, correlates highly with the euglycemic-hyperinsulinemic glucose clamp and the SSPG test. Impaired insulin-mediated whole-body glycolysis is a feature of insulin resistance, which provides a means of assessing insulin sensitivity in vivo.
OBJECTIVE: The purpose of this study was to compare an in vivo test of whole-body glycolysis, the deuterated-glucose disposal test (2H-GDT), with insulin sensitivity measured by the euglycemic-hyperinsulinemic glucose clamp and the steady-state plasma glucose (SSPG) test. RESEARCH DESIGN AND METHODS: The 2H-GDT consists of an oral glucose challenge containing deuterated glucose, followed by measurement of heavy water (2H2O) production, which represents whole-body glycolytic disposal of the glucose load. 2H2O production is corrected for ambient insulin concentration as an index of tissue insulin sensitivity. The 2H-GDT was compared with euglycemic-hyperinsulinemic glucose clamps in healthy lean subjects (n = 8) and subjects with the metabolic syndrome (n = 9) and with the SSPG test in overweight (n = 12) and obese (n = 6) subjects. RESULTS: A strong correlation with the clamp was observed for the 75-g and 30-g 2H-GDT (r = 0.95, P < 0.0001 and r = 0.88, P < 0.0001, respectively). The 2H-GDT and clamp studies revealed marked insulin resistance in subjects with metabolic syndrome compared with lean control subjects. The correlation with the clamp was maintained in each group (lean, r = 0.86, P < 0.01; metabolic syndrome, r = 0.81, P < 0.01) for the 75-g test. The 2H-GDT also correlated strongly with the SSPG test (r = -0.87, P < 0.0001) in overweight and obese subjects. CONCLUSIONS: The 2H-GDT, which measures whole-body glycolysis in humans in a quantitative manner, correlates highly with the euglycemic-hyperinsulinemic glucose clamp and the SSPG test. Impaired insulin-mediated whole-body glycolysis is a feature of insulin resistance, which provides a means of assessing insulin sensitivity in vivo.
Authors: Kimber L Stanhope; Steven C Griffen; Andrew A Bremer; Roel G Vink; Ernst J Schaefer; Katsuyuki Nakajima; Jean-Marc Schwarz; Carine Beysen; Lars Berglund; Nancy L Keim; Peter J Havel Journal: Am J Clin Nutr Date: 2011-05-25 Impact factor: 7.045
Authors: Jose E Galgani; Lilian de Jonge; Jennifer C Rood; Steven R Smith; Andrew A Young; Eric Ravussin Journal: Obesity (Silver Spring) Date: 2010-04-01 Impact factor: 5.002
Authors: C Beysen; E J Murphy; K Deines; M Chan; E Tsang; A Glass; S M Turner; J Protasio; T Riiff; M K Hellerstein Journal: Diabetologia Date: 2011-12-02 Impact factor: 10.122
Authors: Yuya Nishida; Matthew J Rardin; Chris Carrico; Wenjuan He; Alexandria K Sahu; Philipp Gut; Rami Najjar; Mark Fitch; Marc Hellerstein; Bradford W Gibson; Eric Verdin Journal: Mol Cell Date: 2015-06-11 Impact factor: 17.970
Authors: Donald J Roohk; Smita Mascharak; Cyrus Khambatta; Ho Leung; Marc Hellerstein; Charles Harris Journal: Endocrinology Date: 2013-03-14 Impact factor: 4.736
Authors: Elena S F Berman; Susan L Fortson; Steven P Snaith; Manish Gupta; Douglas S Baer; Isabelle Chery; Stephane Blanc; Edward L Melanson; Peter J Thomson; John R Speakman Journal: Anal Chem Date: 2012-11-01 Impact factor: 6.986
Authors: Kimber L Stanhope; Jean Marc Schwarz; Nancy L Keim; Steven C Griffen; Andrew A Bremer; James L Graham; Bonnie Hatcher; Chad L Cox; Artem Dyachenko; Wei Zhang; John P McGahan; Anthony Seibert; Ronald M Krauss; Sally Chiu; Ernst J Schaefer; Masumi Ai; Seiko Otokozawa; Katsuyuki Nakajima; Takamitsu Nakano; Carine Beysen; Marc K Hellerstein; Lars Berglund; Peter J Havel Journal: J Clin Invest Date: 2009-04-20 Impact factor: 14.808